In people suffering from a rare disease the diagnostic process and the confirmation of a final diagnosis is often ongoing for many years. Factors contributing to delayed diagnosis include the limited knowledge of health care professionals about rare diseases and their symptoms but also a psychiatric or psychosomatic (co-)morbidity obscuring the symptoms of the rare disease. The project ZSE-DUO will evaluate whether a combination of an expert in somatic medicine and a psychiatric/psychosomatic specialist will increase the rate of assured diagnoses in patients approaching a center of rare diseases (primary outcome), accelerate the process until a diagnosis is made, reduce the costs of diagnosing a patient, and lead to a higher satisfaction of patients and health care professionals. Furthermore, the project will evaluate whether the use of psychosomatic screening tools at registration of a patient in a center for rare diseases will help to guide the diagnostic process. Two cohorts of 682 patients each will be sequentially recruited over 9 plus 9 months: the Control group cohort (CG based on somatic expertise) and the Experimental group cohort (EG combined psychosomatic/somatic expertise Included will be persons from the age of at least 12 years presenting with symptoms and signs which are not explained by current diagnoses (as judged by the patient's primary care physician and a specialized physician at the center for rare diseases ZSE evaluating the medical records). Patients will be recruited from 11 German Centers for Rare Diseases associated with University hospitals in the cities of Aachen, Bochum, Frankfurt, Hannover, Magdeburg, Mainz, Münster, Regensburg, Tübingen, Ulm and Würzburg. Recruitment will be supported by a collaboration with the German patient organization representing many rare disease organizations ACHSE e.V. and a collaboration with the insurance companies Techniker Krankenkasse, IKK gesund plus and AOK Hessen who also provide data on costs of care. Data collection and analysis will be coordinated and performed by the Institute for Clinical Epidemiology and Biometry at the University of Würzburg, the Institute for Epidemiology, Social Medicine and Science of Health Care Systems in Hannover, and the Department of Medical Psychology in Hamburg. The project is funded by the Innovationsfond of the Federal Joint Committee in Germany.
Study Type
INTERVENTIONAL
Allocation
NON_RANDOMIZED
Purpose
HEALTH_SERVICES_RESEARCH
Masking
NONE
Enrollment
1,379
Two medical experts, one somatic specialist and one psychiatrist/psychosomatic specialist see all medical records and the patients together
Center for Rare Diseases ZESE, University Hospital
Würzburg, Bavaria, Germany
Center for Rare Diseases ZSEA, University Hospital
Aachen, Germany
Center for Rare Diseases CeSER, St. Josef Hospital
Bochum, Germany
LWL-Universitätsklinikum der Ruhr-Universität
Bochum, Germany
Center for Rare Diseases FRZSE, UNiversity Hospital
Frankfurt, Germany
Center for Rare Diseases, Hannover Medical School
Hanover, Germany
Center for Rare Diseases MKSE, Otto von Guericke University
Magdeburg, Germany
Center for Rare Diseases, Medical Center
Mainz, Germany
Center for Rare Diseases, University Hospital
Münster, Germany
Center for Rare Diseases ZSER, University Hospital
Regensburg, Germany
...and 2 more locations
Diagnoses made
The number of diagnoses explaining the symptomatology of the patient made during the evaluation process
Time frame: 12 months after signing the consent form
Time to diagnosis
The time it takes to make a diagnosis
Time frame: 12 months after signing the consent form
Patient satisfaction with diagnostic process using ZUF-8
The patients' satisfaction with the diagnostic process is assessed in the total sample with the questionnaire ZUF-8 (Fragebogen zur Patientenzufriedenheit - patient satisfaction questionnaire) and in a randomly selected subsample of about 40 patients by structured telephone interviews.
Time frame: 12 months after signing the consent form
Costs of the diagnostic process
estimated costs from first contact with the center for rare diseases until a diagnosis explaining the symptoms has been established
Time frame: up to 12 months after signing the consent from
Patients' quality of life using EQ-5D and SF12 (or KIDSCREEN-10 for children)
Change in the patients' quality of life as assessed with the Quality of life questionnaires EQ-5D from the EuroQoL Group in all patients and Short Form 12 (SF-12) in patients 16 years and older. In patients younger than 16 years, the health-related quality of life questionnaire for children and adolescents KIDSCREEN-10 is used.
Time frame: 12 months after signing the consent from
Physician satisfaction with new form of care using new questionnaire
The satisfaction of physicians working in the Centers fro Rare Diseases with the new form of care compared to standard care will be assessed by a newly developed questionnaire administered to all physicians involved in patient care in the 11 centers. For the development of the questionnaire, 3 focus groups of 10 physicians each will be questioned.
Time frame: 30 months after the project start (end of the intervention period)
Value of screening instruments for psychiatric-psychosomatic (co-)morbidities
Performance of screening tools to identify patients with psychiatric-psychosomatic comorbidities against the judgement of a psychiatrist/psychosomatic expert seeing the patient (intervention group only)
Time frame: 30 months after the project start (end of intervention period)
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.